Javascript must be enabled to continue!
Monitoring SARS-CoV-2 seroprevalence over time among pregnant women admitted to delivery units: Suitability for surveillance
View through CrossRef
Objectives
To determine SARS-CoV-2 seroprevalence over time and risk factors among pregnant women at delivery in São Paulo, Brazil; and to evaluate the suitability of pregnant women as a sentinel population for SARS-CoV-2 serosurveillance.
Methods
Unselected consecutive pregnant women presenting at the labor ward of a single large hospital between July 20th 2020 to February 21st 2021 were enrolled and tested for SARS-CoV-2 serology using two assays: the rapid chromatic Wondfo One Step (for total IgA and IgG detection) and Roche Elecsys assay (detecting anti-nucleoprotein [N] IgG). SARS-CoV-2 seroprevalence was computed as smooth spline function over time with 95% confidence intervals (CI). Risk factors were evaluated for positivity by each assay. We compared timepoint seroprevalence by the two assays with four concomitant community household surveys (HHS), in which the Roche assay was used, to determine the sensitivity and relevance of the pregnant women population as sentinel population.
Results
Overall SARS-CoV-2 seroprevalence was 28.9% (221/763) by Roche and 17.9% (137/763) by Wondfo. Reported symptoms experienced during pregnancy were all significantly correlated with being SARS-CoV-2 seropositive at delivery with any assay (with odds-ratios ranging from 3.0 [95% CI: 2.1–4.3] for coryza to 22.8 [95% CI: 12.3–46.6] for ageusia). Seropositivity by either assay was high in women at delivery in the early period of the pandemic (June 2020), compared with seropositivity in women from the concomitant HHS: 44.1% (95% CI: 21.8–66.4) for Roche, 54.1% (30.9–78.5) for Wondfo, versus 11.4% (95% CI: 9.2–13.6) for HHS. For later periods (October 2020 and January 2021), the seropositivity in women at delivery measured by Roche corresponded well with the prevalence found among women in the HHS using the same assay, whilst prevalence measured by Wondfo dropped.
Conclusions
Women at delivery represent a highly exposed and readily accessible population for sentinel surveillance of emerging infections such as SARS-CoV-2.
Title: Monitoring SARS-CoV-2 seroprevalence over time among pregnant women admitted to delivery units: Suitability for surveillance
Description:
Objectives
To determine SARS-CoV-2 seroprevalence over time and risk factors among pregnant women at delivery in São Paulo, Brazil; and to evaluate the suitability of pregnant women as a sentinel population for SARS-CoV-2 serosurveillance.
Methods
Unselected consecutive pregnant women presenting at the labor ward of a single large hospital between July 20th 2020 to February 21st 2021 were enrolled and tested for SARS-CoV-2 serology using two assays: the rapid chromatic Wondfo One Step (for total IgA and IgG detection) and Roche Elecsys assay (detecting anti-nucleoprotein [N] IgG).
SARS-CoV-2 seroprevalence was computed as smooth spline function over time with 95% confidence intervals (CI).
Risk factors were evaluated for positivity by each assay.
We compared timepoint seroprevalence by the two assays with four concomitant community household surveys (HHS), in which the Roche assay was used, to determine the sensitivity and relevance of the pregnant women population as sentinel population.
Results
Overall SARS-CoV-2 seroprevalence was 28.
9% (221/763) by Roche and 17.
9% (137/763) by Wondfo.
Reported symptoms experienced during pregnancy were all significantly correlated with being SARS-CoV-2 seropositive at delivery with any assay (with odds-ratios ranging from 3.
0 [95% CI: 2.
1–4.
3] for coryza to 22.
8 [95% CI: 12.
3–46.
6] for ageusia).
Seropositivity by either assay was high in women at delivery in the early period of the pandemic (June 2020), compared with seropositivity in women from the concomitant HHS: 44.
1% (95% CI: 21.
8–66.
4) for Roche, 54.
1% (30.
9–78.
5) for Wondfo, versus 11.
4% (95% CI: 9.
2–13.
6) for HHS.
For later periods (October 2020 and January 2021), the seropositivity in women at delivery measured by Roche corresponded well with the prevalence found among women in the HHS using the same assay, whilst prevalence measured by Wondfo dropped.
Conclusions
Women at delivery represent a highly exposed and readily accessible population for sentinel surveillance of emerging infections such as SARS-CoV-2.
Related Results
Pregnant Prisoners in Shackles
Pregnant Prisoners in Shackles
Photo by niu niu on Unsplash
ABSTRACT
Shackling prisoners has been implemented as standard procedure when transporting prisoners in labor and during childbirth. This procedure ensu...
Playing Pregnancy: The Ludification and Gamification of Expectant Motherhood in Smartphone Apps
Playing Pregnancy: The Ludification and Gamification of Expectant Motherhood in Smartphone Apps
IntroductionLike other forms of embodiment, pregnancy has increasingly become subject to representation and interpretation via digital technologies. Pregnancy and the unborn entity...
The Women Who Don’t Get Counted
The Women Who Don’t Get Counted
Photo by Hédi Benyounes on Unsplash
ABSTRACT
The current incarceration facilities for the growing number of women are depriving expecting mothers of adequate care cruci...
Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
ABSTRACTThe COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-spe...
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
AbstractBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an emerging disease with fatal outcomes. In this study, a fundamental knowledge gap question is to...
SARS-CoV-2 within-host diversity of human hosts and its implications for viral immune evasion
SARS-CoV-2 within-host diversity of human hosts and its implications for viral immune evasion
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously evolving, bringing great challenges to the control of the virus. In the...
Seroprevalence of SARS-CoV-2(Covid-19) antibody among blood donors in a tertiary care centre in South India
Seroprevalence of SARS-CoV-2(Covid-19) antibody among blood donors in a tertiary care centre in South India
INTRODUCTION The novel severe acute respiratory syndrome virus
2 (SARS-CoV-2), which is responsible Coronavirus disease (COVID-19),
spread worldwide from China, causing a pandemic ...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...

